


Biosample Access

What Type of Biosamples are available for HD Research?
Ask us – we will help you!




* Very limited resource. Analyses ongoing. Access subject to review by Prof. Sarah Tabrizi and CHDI CMO Cristina Sampaio

Study	Summary	Duration	# participants	Participant segment	Lymphoblastoid cell lines LCLs	DNA from whole blood	Ficoll PBMCs	Buffy coat	Plasma	CSF	Cells from CSF	Serum	PAX gene RNA	Buccal swabs	Other
Enroll-HD	Prospective, open-ended, multi-national, multi-center observational study without experimental treatments.	2012-	23,000	<ul style="list-style-type: none"> Manifest HD Pre-manifest HD Genotype negative Genotype unknown Family Control Community Control 	Yes, BL 2012 – Mar 2018	Yes, BL 2012 -	Yes, All 2012 -	No	Yes, EDTA Jul 2019 -	No	No	No	No	No	No
REGISTRY	Prospective, open-ended, European, multi-center observational study without experimental treatments.	2004 - 2017	13,000	<ul style="list-style-type: none"> Manifest HD Pre-manifest HD Genotype negative Genotype unknown Family Control Community Control 	Yes, BL 2005 – Sep 2015	Yes BL: 2005 – Sep 2015 FUP: Apr 2010 – Sep 2015	Yes, All 2005 – Sep 2015	No	No	No	No	No	No	No	No
HDCSF/ HDClarity	Study to collect high-quality CSF samples for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. Enroll-HD platform study.	2017-	550 Goal: 1200	<ul style="list-style-type: none"> Early Pre-manifest HD Late Pre-manifest HD Early Manifest HD Mod Manifest HD Late Manifest HD Control 	No	No	No	No	Yes, LiHep 2017 -	Yes 2017 -	Yes 2017 -	Yes 2017 -	No	No	No
HDYAS	Study to identify and describe the earliest signs of HD-related brain changes and functional impairments.	2017 - 2019	131	<ul style="list-style-type: none"> Early Pre-manifest HD Control 	No	No	No	No	Yes, LiHep	Yes	Yes	Yes	No	No	No
TRACK-HD	Multi-site international study aiming to establish what measurements were the best to use as 'outcome measures' for clinical trials in HD.	2008-2011	402	<ul style="list-style-type: none"> Pre-manifest Early Manifest Control 	Yes, BL 2008	Yes BL: 2008 FUP: 2011	No	Yes, All EDTA	Yes, All EDTA	No	No	No	Yes - 2008 - 2010	No	No
TRACK-ON	Extension of TRACK-HD	2012 – 2014	245	<ul style="list-style-type: none"> Pre-manifest Early Manifest Control 	No	Yes, All	Yes, All CPT	No	Yes, All CPT	No	No	No	Yes - 2014	Yes, All	No
MTM-HD	Multi Tissue Monitoring. Improved insight into disease-specific pathway/network alterations; Analysis of tissue samples from participating individuals will help to identify HD-related signatures	2015 - 2017	60	<ul style="list-style-type: none"> Pre-manifest Early Manifest Control 	No	Yes	No	Yes	Yes, EDTA	No	No	No	No	Yes	Fibroblasts Myoblasts iPS Primary: Skin Muscle Fat

BL: Baseline; FUP: Follow Up

Process to access biosamples



Biosample request managers: Non-renewable: Mette Gilling Nielsen, mette.gilling@enroll-hd.org; Renewable: Christine Capper-Loup, christine.capper-loup@enroll-hd.org